Home >> Research Area >>Natural Products>>Lignans>> (-)-licarin A

(-)-licarin A

CAS# 23518-30-1

(-)-licarin A

Catalog No. BCN5087----Order now to get a substantial discount!

Product Name & Size Price Stock
(-)-licarin A: 5mg $380 In Stock
(-)-licarin A: 10mg Please Inquire In Stock
(-)-licarin A: 20mg Please Inquire Please Inquire
(-)-licarin A: 50mg Please Inquire Please Inquire
(-)-licarin A: 100mg Please Inquire Please Inquire
(-)-licarin A: 200mg Please Inquire Please Inquire
(-)-licarin A: 500mg Please Inquire Please Inquire
(-)-licarin A: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (-)-licarin A

Number of papers citing our products

Chemical structure

(-)-licarin A

3D structure

Chemical Properties of (-)-licarin A

Cas No. 23518-30-1 SDF Download SDF
PubChem ID 5281836 Appearance Powder
Formula C20H22O4 M.Wt 326.4
Type of Compound Lignans Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name 2-methoxy-4-[(2S,3S)-7-methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydro-1-benzofuran-2-yl]phenol
SMILES CC=CC1=CC2=C(C(=C1)OC)OC(C2C)C3=CC(=C(C=C3)O)OC
Standard InChIKey ITDOFWOJEDZPCF-FNINDUDTSA-N
Standard InChI InChI=1S/C20H22O4/c1-5-6-13-9-15-12(2)19(24-20(15)18(10-13)23-4)14-7-8-16(21)17(11-14)22-3/h5-12,19,21H,1-4H3/b6-5+/t12-,19-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of (-)-licarin A

The seeds of Myristica fragrans Houtt.

Biological Activity of (-)-licarin A

DescriptionLicarin A and (-)-Licarin A are promising compounds that could be used for the development of schistosomicidal and trypanocidal agents; Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro; (-)-Licarin A has antimycobacterial activity, represents a potentially active anti-tuberculosis agent to treat MDR M. tuberculosis and NTM strains.Licarin A significantly protects primary cultured neuronal cells against glutamate-induced oxidative stress, via antioxidative activities.
TargetsDNA/RNA Synthesis | IL Receptor | Antifection
In vitro

Meso-dihydroguaiaretic acid and licarin A of Machilus thunbergii protect against glutamate-induced toxicity in primary cultures of a rat cortical cells.[Pubmed: 16151440]

Br J Pharmacol. 2005 Nov;146(5):752-9.

We previously reported that four lignans isolated from the bark of Machilus thunbergii Sieb. et Zucc. (Lauraceae) protected primary cultures of rat cortical neurons from neurotoxicity induced by glutamate.
METHODS AND RESULTS:
2 Among the lignans, meso-dihydroguaiarectic acid (MDGA) and Licarin A significantly attenuated glutamate-induced neurotoxicity when added prior to or right after the excitotoxic glutamate challenge. 3 The neuroprotective activities of two lignans appeared to be more effective in protecting neurons against neurotoxicity induced by NMDA than that induced by kainic acid. 4 MDGA and Licarin A diminished the calcium influx that routinely accompanies with the glutamate-induced neurotoxicity, and inhibited the subsequent overproduction of cellular nitric oxide and peroxide to the level of control cells. They also preserved cellular activities of antioxidative enzymes such as superoxide dismutase, glutathione peroxidase and glutathione reductase reduced in the glutamate-injured neuronal cells.
CONCLUSIONS:
5 Thus, our results suggest that MDGA and Licarin A significantly protect primary cultured neuronal cells against glutamate-induced oxidative stress, via antioxidative activities.

Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.[Pubmed: 23891943]

Exp Parasitol. 2013 Oct;135(2):307-13.

Leishmaniasis' treatment is based mostly on pentavalent antimonials or amphotericin B long-term administration, expensive drugs associated with severe side effects. Considering these aforementioned, the search for alternative effective and safe leishmaniasis treatments is a necessity.
METHODS AND RESULTS:
This work evaluated a neolignan, Licarin A anti-leishmanial activity chemically synthesized by our study group. It was observed that Licarin A effectively inhibited Leishmania (Leishmania) major promastigotes (IC₅₀ of 9.59 ± 0.94 μg/mL) growth, by inducing in these parasites genomic DNA fragmentation in a typical death pattern by apoptosis. Additionally, the neolignan proved to be even more active against intracellular amastigotes of the parasite (EC₅₀ of 4.71 ± 0.29 μg/mL), and significantly more effective than meglumine antimoniate (EC₅₀ of 216.2 ± 76.7 μg/mL) used as reference drug. The antiamastigote activity is associated with an immunomodulatory activity, since treatment with Licarin A of the infected macrophages induced a decrease in the interleukin (IL)-6 and IL-10 production.
CONCLUSIONS:
This study demonstrates for the first time the antileishmanial activity of Licarin A and suggests that the compound may be a promising in the development of a new leishmanicidal agent.

Schistosomicidal and trypanocidal structure-activity relationships for (±)-licarin A and its (-)- and (+)-enantiomers.[Pubmed: 21570099]

Phytochemistry. 2011 Aug;72(11-12):1424-30.

(±)-Licarin A (1) was obtained by oxidative coupling, and its enantiomers, (-)-Licarin A (2) and (+)-Licarin A (3), were resolved by chiral HPLC.
METHODS AND RESULTS:
Schistosomicidal and trypanocidal activities of these compounds were evaluated in vitro against Schistosoma mansoni adult worms and trypomastigote forms of Trypanosoma cruzi. The racemic mixture (1) displayed significant schistosomicidal activity with an LC₅₀ value of 53.57 μM and moderate trypanocidal activity with an IC₅₀ value of 127.17 μM. On the other hand, the (-)-enantiomer (2), displaying a LC₅₀ value of 91.71 μM, was more active against S. mansoni than the (+)-enantiomer (3), which did not show activity. For the trypanocidal assay, enantiomer 2 showed more significant activity (IC₅₀ of 23.46 μM) than enantiomer 3, which showed an IC₅₀ value of 87.73 μM.
CONCLUSIONS:
Therefore, these results suggest that (±)-Licarin A (1) and (-)-Licarin A (2) are promising compounds that could be used for the development of schistosomicidal and trypanocidal agents.

Protocol of (-)-licarin A

Animal Research

Antitubercular activity and the subacute toxicity of (-)-Licarin A in BALB/c mice: a neolignan isolated from Aristolochia taliscana.[Pubmed: 23291382]

Arch Med Res. 2013 Feb;44(2):99-104.

(-)-Licarin A (LA) was isolated from diverse plants such as Aristolochia taliscana and possesses antimycobacterial, antiinflammatory, trypanocidal, and neuroprotective activities. The aim of the study was to determine the antitubercular and subacute toxicity of (-)-Licarin A isolated from A. taliscana in BALB/c mice.
METHODS AND RESULTS:
The antitubercular activity of (-)-Licarin A was tested in a TB murine model inducing disease with M. tuberculosis H37Rv or MDR. Mice were treated with (-)-Licarin A (5 mg/kg) for 30 and 60 days; post/treatment, lung bacilli loads and pneumonia percentage were determined. The subacute toxicity of (-)-Licarin A (21 days) was evaluated in healthy mice. After treatment, biochemical and hematological parameters were determined and main organs were analyzed histologically. In animals infected with drug-sensitive or MDR strains, (-)-Licarin A produced a significant decrease of pulmonary bacillary burdens at day 30 of treatment, and a significant pneumonia reduction at days 30 and 60 of treatment. Regarding subacute toxicity, (-)-Licarin A administration during 21 days showed no abnormalities in main-organ macro- and microarchitecture.
CONCLUSIONS:
(-)-Licarin A reduces pneumonia of mice infected with both mycobacterium strains. Also, subacute toxicity of (-)-Licarin A exhibits no major signs of damage. Biochemical and hematological parameters and histological analyses indicate that (-)-Licarin A caused no significant changes at the doses assayed.

(-)-licarin A Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(-)-licarin A Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (-)-licarin A

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0637 mL 15.3186 mL 30.6373 mL 61.2745 mL 76.5931 mL
5 mM 0.6127 mL 3.0637 mL 6.1275 mL 12.2549 mL 15.3186 mL
10 mM 0.3064 mL 1.5319 mL 3.0637 mL 6.1275 mL 7.6593 mL
50 mM 0.0613 mL 0.3064 mL 0.6127 mL 1.2255 mL 1.5319 mL
100 mM 0.0306 mL 0.1532 mL 0.3064 mL 0.6127 mL 0.7659 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on (-)-licarin A

Schistosomicidal and trypanocidal structure-activity relationships for (+/-)-licarin A and its (-)- and (+)-enantiomers.[Pubmed:21570099]

Phytochemistry. 2011 Aug;72(11-12):1424-30.

(+/-)-Licarin A (1) was obtained by oxidative coupling, and its enantiomers, (-)-licarin A (2) and (+)-licarin A (3), were resolved by chiral HPLC. Schistosomicidal and trypanocidal activities of these compounds were evaluated in vitro against Schistosoma mansoni adult worms and trypomastigote forms of Trypanosoma cruzi. The racemic mixture (1) displayed significant schistosomicidal activity with an LC(5)(0) value of 53.57 muM and moderate trypanocidal activity with an IC(5)(0) value of 127.17 muM. On the other hand, the (-)-enantiomer (2), displaying a LC(5)(0) value of 91.71 muM, was more active against S. mansoni than the (+)-enantiomer (3), which did not show activity. For the trypanocidal assay, enantiomer 2 showed more significant activity (IC(5)(0) of 23.46 muM) than enantiomer 3, which showed an IC(5)(0) value of 87.73 muM. Therefore, these results suggest that (+/-)-licarin A (1) and (-)-licarin A (2) are promising compounds that could be used for the development of schistosomicidal and trypanocidal agents.

Antitubercular activity and the subacute toxicity of (-)-Licarin A in BALB/c mice: a neolignan isolated from Aristolochia taliscana.[Pubmed:23291382]

Arch Med Res. 2013 Feb;44(2):99-104.

BACKGROUND AND AIMS: Tuberculosis remains a worldwide health problem and requires long-term treatment with several antibiotics; therefore, compliance problems and the emergence of multidrug resistance (MDR) are involved. (-)-licarin A (LA) was isolated from diverse plants such as Aristolochia taliscana and possesses antimycobacterial, antiinflammatory, trypanocidal, and neuroprotective activities. The aim of the study was to determine the antitubercular and subacute toxicity of LA isolated from A. taliscana in BALB/c mice. METHODS: The antitubercular activity of LA was tested in a TB murine model inducing disease with M. tuberculosis H37Rv or MDR. Mice were treated with LA (5 mg/kg) for 30 and 60 days; post/treatment, lung bacilli loads and pneumonia percentage were determined. The subacute toxicity of LA (21 days) was evaluated in healthy mice. After treatment, biochemical and hematological parameters were determined and main organs were analyzed histologically. RESULTS: In animals infected with drug-sensitive or MDR strains, LA produced a significant decrease of pulmonary bacillary burdens at day 30 of treatment, and a significant pneumonia reduction at days 30 and 60 of treatment. Regarding subacute toxicity, LA administration during 21 days showed no abnormalities in main-organ macro- and microarchitecture. Biochemical and hematological parameters analyzed showed no statistical differences between control and treated groups. CONCLUSIONS: (-)-licarin A reduces pneumonia of mice infected with both mycobacterium strains. Also, subacute toxicity of LA exhibits no major signs of damage. Biochemical and hematological parameters and histological analyses indicate that LA caused no significant changes at the doses assayed.

Meso-dihydroguaiaretic acid and licarin A of Machilus thunbergii protect against glutamate-induced toxicity in primary cultures of a rat cortical cells.[Pubmed:16151440]

Br J Pharmacol. 2005 Nov;146(5):752-9.

1 We previously reported that four lignans isolated from the bark of Machilus thunbergii Sieb. et Zucc. (Lauraceae) protected primary cultures of rat cortical neurons from neurotoxicity induced by glutamate. 2 Among the lignans, meso-dihydroguaiarectic acid (MDGA) and licarin A significantly attenuated glutamate-induced neurotoxicity when added prior to or right after the excitotoxic glutamate challenge. 3 The neuroprotective activities of two lignans appeared to be more effective in protecting neurons against neurotoxicity induced by NMDA than that induced by kainic acid. 4 MDGA and licarin A diminished the calcium influx that routinely accompanies with the glutamate-induced neurotoxicity, and inhibited the subsequent overproduction of cellular nitric oxide and peroxide to the level of control cells. They also preserved cellular activities of antioxidative enzymes such as superoxide dismutase, glutathione peroxidase and glutathione reductase reduced in the glutamate-injured neuronal cells. 5 Thus, our results suggest that MDGA and licarin A significantly protect primary cultured neuronal cells against glutamate-induced oxidative stress, via antioxidative activities.

Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.[Pubmed:23891943]

Exp Parasitol. 2013 Oct;135(2):307-13.

Leishmaniasis' treatment is based mostly on pentavalent antimonials or amphotericin B long-term administration, expensive drugs associated with severe side effects. Considering these aforementioned, the search for alternative effective and safe leishmaniasis treatments is a necessity. This work evaluated a neolignan, licarin A anti-leishmanial activity chemically synthesized by our study group. It was observed that licarin A effectively inhibited Leishmania (Leishmania) major promastigotes (IC(5)(0) of 9.59 +/- 0.94 mug/mL) growth, by inducing in these parasites genomic DNA fragmentation in a typical death pattern by apoptosis. Additionally, the neolignan proved to be even more active against intracellular amastigotes of the parasite (EC(5)(0) of 4.71 +/- 0.29 mug/mL), and significantly more effective than meglumine antimoniate (EC(5)(0) of 216.2 +/- 76.7 mug/mL) used as reference drug. The antiamastigote activity is associated with an immunomodulatory activity, since treatment with licarin A of the infected macrophages induced a decrease in the interleukin (IL)-6 and IL-10 production. This study demonstrates for the first time the antileishmanial activity of licarin A and suggests that the compound may be a promising in the development of a new leishmanicidal agent.

Description

(±)-Licarin A ((±)-trans-Dehydrodiisoeugenol) is a dihydrobenzofuran neolignan, the resultant of an oxidative coupling reaction of isoeugenol and horseradish peroxidase (HRP) enzyme. (±)-Licarin A displays 58.7% parasite lysis and has an IC50 value of 100.8 µM for trypanocidal activity against trypomastigote forms of T. cruzi. And (±)-Licarin A shows 100% parasites mortality at 200 µM.

Keywords:

(-)-licarin A,23518-30-1,Natural Products, buy (-)-licarin A , (-)-licarin A supplier , purchase (-)-licarin A , (-)-licarin A cost , (-)-licarin A manufacturer , order (-)-licarin A , high purity (-)-licarin A

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: